Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy?

Publisher： Karger

E-ISSN： 2296-5262|30|1-2|39-42

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.1-2, 2007-01, pp. : 39-42

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin?

By  

Oncology Research and Treatment, Vol. 26, Iss. 5, 2003-11 ,pp. : 462-467

Karger

Access to resources Recommend Favorite

CA19-9 as a Serum Marker for Poor Prognosis in Urothelial Carcinoma

By  

Urologia Internationalis, Vol. 73, Iss. 4, 2004-12 ,pp. : 357-357

Karger

Access to resources Recommend Favorite

CA19-9 as a Serum Marker for Poor Prognosis in Urothelial Carcinoma

By  

Urologia Internationalis, Vol. 72, Iss. 2, 2004-02 ,pp. : 112-117

Karger

Access to resources Recommend Favorite

Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic Pancreatitis

By  

Pancreatology, Vol. 10, Iss. 6, 2011-01 ,pp. : 689-694

Karger

Access to resources Recommend Favorite

Serum HCGβ and CA 72-4 Are Stronger Prognostic Factors than CEA, CA 19-9 and CA 242 in Pancreatic Cancer

By  

Oncology, Vol. 66, Iss. 2, 2004-05 ,pp. : 126-131

Karger

Access to resources Recommend Favorite